Bridging the Gap Between Science and the Law

Genetic Evidence Concerning Causation for Mesothelioma 16 June 2020 at 2pm Eastern Daylight Time Click Here For More Information and to Register The use of genomics in personal injury cases continues to accelerate, especially including mesothelioma cases. A panel of five speakers will present defense views, plaintiff views, legal rulings, and science on the use

Plaintiff experts having been asserting for decades that all mesotheliomas must be linked to some asbestos exposure. Indeed, this has led to the erroneous (but widespread) view that mesothelioma is a signature disease, only caused by asbestos exposure. This viewpoint ignores the well documented fact that cancer is a disease of the genome and mesothelioma

The ToxicoGenomica team has brought genomic causation analysis into over 30 cancer cases for defendants in cases involving benzene, radiation, and asbestos (see here for a description of five of the older cases). Lately, we have noticed an upward trend of prominent plaintiff law firms investing heavily in arguing the genetics of cancer, including working

Innovative Science Solutions has been closely following the peer-reviewed scientific literature related to COVID-19. To this end, we have launched a free SARS-CoV-2/coronovirus/COVID-19 science library that will be updated on a weekly basis. Given the high volume of newly published scientific literature on this topic, our goal is to gather the latest scientific findings and

A valuable web  site illustrates the power and speed of using virus genomes to track and understand the global spread of #Covid19. Data includes 723 open access virus genomes and was updated 3/20. To use preprogrammed learning modules on the site, use cursor to pull up and down on the left hand side. https://nextstrain.org/narratives/ncov/sit-rep/2020-03-20 Courtesy of

This article was co-authored by Steve J. Bannister, PhD, of Hightower Pharmaceutical Services. He has over thirty years of experience applying the fundamentals of physical and analytical chemistry to development of drug-delivery devices. His projects have included the development of a standardized e-cigarette for use in NIH-sponsored clinical studies.  Electronic nicotine-delivery systems (ENDS or e-cigarettes)

On September 9-11, Dr. Len van Zyl of ToxicoGenomica will be speaking at Perrin Conferences’ National Asbestos Litigation Conference at the  Fairmont San Francisco Hotel, San Francisco, CA. This marks the tenth anniversary of the three-day conference which provides attendees with a deeper understanding of the trends currently driving asbestos litigation and the impact these

E-Cigarette Expert Witness Teams Will be Key as Litigation Increases E-cigarettes and other reduced risk nicotine products (such as smokeless tobacco, heated tobacco, and tobacco-free nicotine products) have generated enormous interest across a spectrum of stakeholders, including smokers who have reportedly quit smoking using one or more of these new (potentially) reduced risk products. Regulators

In a recently published article, Pizzurro and colleagues report several important interspecies differences in perfluoroalkyl substances (PFAS) toxicokinetics. These data represent some of the first evidence for variation in absorption, distribution, metabolism, and excretion (ADME) of PFAS across different species. For PFAS defendants, this paper provides support that pharmacokinetics must be taken into consideration when

This post was co-authored with Tova Werblowsky, Ph.D., a computational physical chemist and associate professor of chemistry at Touro College What are PFAS? Per- and polyfluoroalkyl substances (PFAS) are a diverse group of chemical compounds that resist degradation in the environment. Because PFAS are impervious to water and heat, these compounds have been used in